Valuation: CEL-SCI Corporation

Market Cap 2.94Cr 2.58Cr 2.43Cr 2.22Cr 4.15Cr 281.53Cr 4.18Cr 29Cr 11Cr 143.83Cr 11Cr 11Cr 462.25Cr P/E 2026 *
-0.54x
P/E 2027 * -0.26x
Enterprise Value 2.38Cr 2.09Cr 1.97Cr 1.8Cr 3.37Cr 228.3Cr 3.39Cr 24Cr 9.15Cr 116.63Cr 8.94Cr 8.75Cr 374.84Cr EV / Sales 2026 *
-
EV / Sales 2027 * 4.02x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-14.33% - - 2.94Cr
-3.30%+1.50%+51.24%+99.26% 7.23TCr
+1.25%-3.01%+40.12%+77.12% 6.02TCr
+2.12%+5.26%+32.50%+21.28% 2.77TCr
-3.06%-1.81%-13.10%+357.06% 2.57TCr
-0.75%+2.56%+0.45%-4.46% 2.47TCr
+0.40%+0.75%+22.91%-9.68% 2.07TCr
-1.70%-2.12%+146.86%+314.52% 1.51TCr
+0.36%-0.34%+50.32%+166.42% 1.44TCr
+0.21%+1.17%-8.07%+499.10% 1.42TCr
Average -0.48%+0.44%+35.92%+168.96% 3.06TCr
Weighted average by Cap. -0.77%+0.31%+36.31%+129.11%

Financials

2026 *2027 *
Net sales - 59.72L 52.4L 49.49L 45.1L 84.43L 57Cr 85.04L 5.92Cr 2.29Cr 29Cr 2.24Cr 2.19Cr 94Cr
Net income -2.51Cr -2.2Cr -2.08Cr -1.89Cr -3.55Cr -240.42Cr -3.57Cr -25Cr -9.64Cr -122.82Cr -9.42Cr -9.21Cr -394.74Cr -2.95Cr -2.59Cr -2.45Cr -2.23Cr -4.17Cr -282.88Cr -4.2Cr -29Cr -11Cr -144.52Cr -11Cr -11Cr -464.46Cr
Net Debt -55.54L -48.74L -46.03L -41.95L -78.52L -53Cr -79.08L -5.51Cr -2.13Cr -27Cr -2.09Cr -2.04Cr -87Cr -53.39L -46.85L -44.25L -40.32L -75.48L -51Cr -76.02L -5.29Cr -2.05Cr -26Cr -2Cr -1.96Cr -84Cr
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-